Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

The agency announced on November 2, 2011 that it had approved Edwards Lifesciences' first-generation Sapien TAVR device for patients with severe aortic stenosis who are ineligible for open-heart ...

In particular, research on Edwards' market-leading Sapien TAVR device suggests that the learning curve is 200 cases. That's the inflection point where the physician can deliver optimal patient ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. Investors remain bullish on ...

Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

TMTT sales surged 77% in 2023 to $352M, driven by PASCAL and EVOQUE adoption. TAVR sales reached $1.04B in Q4, up 5.3% year-over-year. Every week, our Whisper Index uncovers five overlooked stocks ...

First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treati ...